SAN DIEGO--Sural nerve grafting is a new procedure that may allow prostate patients undergoing radical prostatectomy to maintain sexual potency. With limited information currently available about the procedure, the ambulatory nurse’s role in educating these patients can be critical in alleviating anxiety and stress, said Mary Schoen, RN, MSN, MPH, a clinical nurse in Memorial Sloan-Kettering Cancer Center’s Urology Department.
SAN DIEGO--Sural nerve grafting is a new procedure that may allow prostate patients undergoing radical prostatectomy to maintain sexual potency. With limited information currently available about the procedure, the ambulatory nurse’s role in educating these patients can be critical in alleviating anxiety and stress, said Mary Schoen, RN, MSN, MPH, a clinical nurse in Memorial Sloan-Kettering Cancer Center’s Urology Department.
Ms. Schoen and her colleague, Dominique DePalma, RN, MA, OCN, also a clinical nurse in the Urology Department, discussed the importance of providing support and education to this population at the 26th Annual Conference of the Oncology Nursing Society (abstract 72).
If tumor invasion into the neurovascular bundle branches is detected during surgery, the nerves allowing erectile function must be resected.
"For men unable to have nerve-sparing surgery, the surgeon will perform a sural nerve graft, taking a nerve from around the ankle bone and placing it around the prostate," Ms. Schoen said. Sural nerve graft patients are expected to regain erectile function within 14 to 18 months after the surgery.
Patients are extremely nervous prior to the surgery and even after surgery, the nurses said. "We get a lot of phone calls. They need a great deal of support," Ms. Schoen said. "Our job is to provide patient education, do referrals to erectile dysfunction specialists, start them on Viagra, and just reassure them." Ms. DePalma noted that the men who have the surgery have more advanced cancer than other patients, so they may need more education and support.
Said Ms. Schoen: "We’re educating other nurses about this new procedure so that they, in turn, can help alleviate patient concerns and make the appropriate referrals."
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.